These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 30333163)

  • 1. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E;
    Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
    Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
    Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E;
    Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years.
    Ghadiri F; Sahraian MA; Baghbanian SM; Ashtari F; Razazian N; Majdinasab N; Poursadeghfard M; Hatamian H; Harirchian MH; Beladimoghadam N; Azimi A; Sharifipour E; Hosseini S; Bayati A; Kamali H; Hosseni Nejad Mir N; Faraji F; Mozhdehipanah H; Modara F; Navardi S; Heidari H; Ayoubi S; Naser Moghadasi A; Eskandarieh S
    Mult Scler Relat Disord; 2022 May; 61():103777. PubMed ID: 35390594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
    Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
    JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
    Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
    Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.